AKT1 and familial pancreatic carcinoma: Zhao et al., through rigorous scientific experiments, demonstrated that activating the GLP-1 receptor with liraglutide exerted an anti-tumor effect on human pancreatic cancer by inhibiting the PI3K/AKT pathway [30].